Products - Blood conditions | Topic

Showing 19 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Gout
Status:
Awaiting development
Expected publication date:
TBC
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Status:
Awaiting development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Pernicious anaemia
Status:
Awaiting development
Expected publication date:
TBC
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olezarsen for treating familial chylomicronaemia syndrome [TSID11993]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [TSID12144]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

What we do

Into practice

Who we are

Blood conditions Products

Showing 19 products

Gout

OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Pernicious anaemia

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]

Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]

Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642]

Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]

Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]

MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]

Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]

Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]

Olezarsen for treating familial chylomicronaemia syndrome [TSID11993]

Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [TSID12144]

Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Blood conditions Products

Showing 19 products